Influence of modified natural and synthetic surfactant preparations on bacterial killing by polymorphonuclear leucocytes

Immunobiology

Volumn 209, Issue 8, 2004, Pages 609-617

  Rauprich, Petra ^a   Walter, Gabriele ^b   Jarstrand, Connie ^c   Robertson, Bengt ^c   Herting, Egbert ^b,c  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b UNIVERSITY OF LÜBECK   (Germany)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Bacteria; Killing; Leucocytes; Pulmonary surfactants

Indexed keywords

BERACTANT; DIPALMITOYLPHOSPHATIDYLCHOLINE; HEXADECANOL; LUNG SURFACTANT; PORACTANT; PUMACTANT; REACTIVE OXYGEN METABOLITE; TYLOXAPOL;

ARTICLE; BACTERIAL COUNT; BACTERICIDAL ACTIVITY; BACTERIUM CULTURE; BIOPHYSICS; CELL ISOLATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG FORMULATION; ESCHERICHIA COLI; HOST RESISTANCE; HUMAN; HUMAN CELL; INCUBATION TIME; NEWBORN PERIOD; NITROBLUE TETRAZOLIUM TEST; NONHUMAN; PHAGOCYTOSIS; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL; SPECIES DIFFERENCE; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS AGALACTIAE;

EID: 11244261268     PISSN: 01712985     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imbio.2004.09.002     Document Type: Article

References (47)

1. Babu, K.S., Woodcock, D.A., Smith, S.E., Staniforth, J.N., Holgate, S.T., Conway, J.H., 2003. Inhaled synthetic surfactant abolishes the early allergen-induced response in asthma. Eur. Respir. J. 21, 1046-1049.
2. Baker, C.J., Edwards, M.S., 2001. Group B streptococcal infections. In: Remington, J.S., Klein, J.O. (Eds.), Infectious Diseases of the Fetus and Newborn Infant, fifth ed. B. Saunders, Philadelphia, pp. 1091-1156.
3. Bellanti, J.A., Nerurkar, L.S., Zeligs, B.J., 1979. Host defenses in the fetus and neonate: studies of the alveolar macrophage during maturation. Pediatrics 64, 726-739.
4. Boncuk-Dayanikli, P., Taeusch, H.W., 1995. Essential and nonessential constituents of exogenous surfactants. In: Robertson, B., Taeusch, H.W. (Eds.), Surfactant Therapy for Lung Disease. Marcel Dekker, New York, pp. 217-238.
5. Findlay, R.D., Taeusch, H.W., David-Cu, R., Walther, F.J., 1995. Lysis of red blood cells and alveolar epithelial toxicity by therapeutic pulmonary surfactants. Pediatr. Res. 37, 26-30.
6. Gan, X.Z., Jarstrand, C., Herting, E., Berggren, P., Robertson, B., 2001. Effect of surfactant and specific antibody on bacterial proliferation and lung function in experimental pneumococcal pneumonia. Int. J. Infect. Dis. 5, 9-18.
7. Goerke, J., 1998. Pulmonary surfactant: functions and molecular composition. In: van Golde, L.M.G. (Ed.), Pulmonary Surfactant: from Surface Chemistry via Biochemistry to Clinical Practice. Elsevier Science Publishers, Amsterdam, pp. 79-89.
8. Golioto, A., Wright, J.R., 2002. Effects of surfactant lipids and surfactant protein A on host defense functions of rat alveolar macrophages. Pediatr. Res. 51, 220-227.
9. Håkansson, S., Granlund Edstedt, M., Sellin, M., Holm, S.E., 1990. Demonstration and characterization of buoyant-density subpopulations of group B streptococcus type III. J. Infect. Dis. 161, 741-746.
10. Herting, E., Jarstrand, C., Rasool, O., Curstedt, T., Sun, B., Robertson, B., 1994. Experimental neonatal group B streptococcal pneumonia: effect of a modified porcine surfactant on bacterial proliferation in ventilated near-term rabbits. Pediatr. Res. 36, 784-791.
11. Herting, E., Jarstrand, C., Rasool, O., Håkansson, S., Curstedt, T., Robertson, B., 1995. Effect of surfactant on nitroblue tetrazolium (NBT) reduction of polymorphonuclear leucocytes stimulated by opsonized type Ia group B streptococci. Acta Paediatr. 84, 922-926.
12. Herting, E., Sun, B., Jarstrand, C., Curstedt, T., Robertson, B., 1997. Surfactant improves lung function and mitigates bacterial growth in immature ventilated rabbits with experimentally induced neonatal group B streptococcal pneumonia. Arch. Dis. Child. 76, F3-F8.
13. Herting, E., Gan, X.Z., Rauprich, P., Jarstrand, C., Robertson, B., 1999. Combined treatment with surfactant and specific immunoglobulin reduces bacterial proliferation in experimental neonatal group B-streptococcal pneumonia. Am. J. Respir. Crit. Care Med. 159, 1862-1867.
14. Herting, E., Gefeller, O., Land, M., van Sonderen, L., Harms, K., Robertson, B., and members of the Collaborative European Multicenter Study Group, 2000. Surfactant treatment of neonates with respiratory failure and group B streptococcal infection. Pediatrics 106, 957-964.
15. Herting, E., Möller, O., Schiffmann, J.H., Robertson, B., 2002. Surfactant improves oxygenation in infants and children with pneumonia and acute respiratory distress syndrome. Acta Paediatr. 91, 1174-1178.
16. Hoidal, JR., Schmeling, D., Peterson, P.K., 1981. Phagocytosis, bacterial killing, and metabolism by purified human lung phagocytes. J. Infect. Dis. 144, 61-71.
17. Jelinkovà, J., 1977. Group B streptococci in the human population. Curr. Top. Microbiol. Immunol. 76, 126-165.
18. Jobe, A.H., 1993. Pulmonary surfactant therapy. N. Engl. J. Med. 328, 861-868.
19. Johansson, J., 1994. The proteins of the surfactant system. Eur. Respir. J. 7, 372-391.
20. Juers, J.A., Rogers, R.M., McCurdy, J.B., Cook, W.W., 1976. Enhancement of bactericidal capacity of alveolar macrophages by human alveolar lining material. Clin. Invest. 58, 271-275.
21. Kaser, M.R., Skouteris, G.G., 1997. Inhibition of bacterial growth by synthetic SP-B1-78 peptides. Peptides 18, 1441-1444.
22. LaForce, F.M., Boose, D.S., 1981. Sublethal damage of Escherichia coli by lung lavage. Am. Rev. Respir. Dis. 124, 733-737.
23. McCormack, F.X., Whitsett, J.A., 2002. The pulmonary collections, SP-A and SP-D, orchestrate innate immunity in the lung. J. Clin. Invest. 109, 707-712.
24. Möller, J.C., Schaible, T., Roll, C., Schiffmann, J.-H., Bindl, L., Schrod, L., Reiss, I., Kohl, M., Demirakca, S., Hentschel, R., Paul, T., Vierzig, A., Groneck, P., von Seefeld, H., Schumacher, H., Gortner, L., Surfactant ARDS Study Group, 2000. Treatment with bovine surfactant in severe acute respiratory distress syndrome in children: a randomized multicenter study. Intens. Care Med. 29, 437-444.
25. Neumeister, B., Woerndle, S., Bartmann, P., 1996. Effects of different surfactant preparations on bacterial growth in vitro. Biol. Neonate 70, 128-134.
26. Phelps, D.S., 2001. Surfactant regulation of host defense function in the lung: a question of balance. Pediatr. Pathol. Mol. Med. 20, 269-292.
27. Philip, A.G.S., 1994. The changing face of neonatal infection: experience at a regional medical center. Pediatr. Infect. Dis. J. 13, 1098-1102.
28. Rauprich, P., Möller, O., Walter, G., Herting, E., Robertson, B., 2000. Influence of modified natural or synthetic surfactant preparations on the growth of bacteria causing infections in the neonatal period. Clin. Diag. Lab. Immunol. 7, 817-822.
29. Scholtes, U., Wiegand, N., Zwirner, J., Herting, E., 2002. Influence of porcine natural modified surfactant on chemotaxis and oxidative metabolism of polymorphonuclear leucocytes. Immun. Biol. 205, 290-302.
30. Seeger, W., Grube, C., Günther, A., Schmidt, R., 1993. Surfactant inhibition by plasma proteins: differential sensitivity of various surfactant preparations. Eur. Respir. J. 6, 971-977.
31. Sherman, M.P., Ganz, T., 1992. Host defense in pulmonary alveoli. Annu. Rev. Physiol. 54, 331-350.
32. Sherman, M.P., Campbell, L.A., Merritt, T.A., Long, W.A., Gunkel, J.H., Curstedt, T., Robertson, B., 1994. Effect of different surfactants on pulmonary group B streptococcal infection in premature rabbits. J. Pediatr. 125, 939-947.
33. Song, G.W., Robertson, B., Curstedt, T., Gan, X.Z., Huang, W.X., 1996. Surfactant treatment in experimental Escherichia coli pneumonia. Acta Anaesthesiol. Scand. 40, 1152-1159.
34. Sordelli, D.O., Zeligs, B.J., Cerquetti, M.C., Morris Hooke, A., Bellanti, J.A., 1985. Inflammatory responses to Pseudomonas aeruginosa and Staphylococcus aureus in the murine lung. Eur. J. Respir. Dis. 66, 31-39.
35. Speer, C.P., Goetze, B., Robertson, B., Curstedt, T., 1991a. The effect of natural porcine surfactant (Curosurf) on the phagocytosis-associated functions of human neutrophilic granulocytes. In: Cosmi, E.V., Di Renzo, G.C., Anceschi, M.M. (Eds.), The Surfactant System of the Lung. Prevention and Treatment of Neonatal and Adult Respiratory Distress Syndrome. Macmillan Press, London, pp. 142-150.
36. Speer, C.P., Goetze, B., Curstedt, T., Robertson, B., 1991b. Phagocytic functions and tumor necrosis factor secretion of human monocytes exposed to natural porcine surfactant (Curosurf). Pediatr. Res. 30, 69-74.
37. Tegtmeyer, F.K., Gortner, L., Ludwig, A., Brandt, E., 1996. In vitro modulation of induced neutrophil activation by different surfactant preparations. Eur. Respir. J. 9, 752-757.
38. Thomassen, M.J., Meeker, D.P., Antal, J.M., Connors, M.J., Wiedemann, H.P., 1992. Synthetic surfactant (Exosurf) inhibits endotoxin-stimulated cytokine secretion by human alveolar macrophages. Am. J. Respir. Cell Mol. Biol. 7, 257-260.
39. Thomassen, M.J., Antal, J.M., Divis, L.T., Wiedemann, H.P., 1995. Regulation of human alveolar macrophage inflammatory cytokines by tyloxapol: a component of the synthetic surfactant Exosurf. Clin. Immunol. Immunopathol. 77, 201-205.
40. Van Golde, L.M.G., 1995. Potential role of surfactant proteins A and D in innate lung defense against pathogens. Biol. Neonate 67 (Suppl. 1), 2-17.
41. Walmrath, D., Günther, A., Ghofrani, H.A., Schermuly, R., Schneider, T., Grimminger, F., Seeger, W., 1996. Bronchoscopic surfactant administration in patients with severe adult respiratory distress syndrome and sepsis. Am. J. Respir. Crit. Care Med. 154, 57-62.
42. Walti, H., Polla, B.S., Bachelet, M., 1997. Modified natural porcine surfactant inhibits superoxide anions and proinflammatory mediators released by resting and stimulated human monocytes. Pediatr. Res. 41, 114-119.
43. Wang, Y., Griffith, W.J., Curstedt, T., Johansson, J., 1999. Porcine pulmonary surfactant preparations contain the antibacterial peptide prophenin and a C-terminal 18-residue fragment thereof. FEBS Lett. 460, 257-262.
44. Wang, Y., Herting, E., Agerberth, B., Johansson, J., 2004. Antibacterial activity of the cathelicidins prophenin (62-79) and LL-37 in the presence of a lung surfactant preparation. Antimicrob. Agents Chemother. 48, 2097-2100.
45. Wilsher, M.L., Parker, D.J., Haslam, P.L., 1990. Immunosuppression by pulmonary surfactant: mechanisms of action. Thorax 45, 3-8.
46. Wright, J.R., 1997. Immunomodulatory functions of surfactant. Physiol. Rev. 77, 931-962.
47. Wright, J.R., 2003. Pulmonary surfactant, a front line of lung host defense. J. Clin. Invest. 111, 1453-1455.